EU/3/20/2329

About

On 21 August 2020, orphan designation EU/3/20/2329 was granted by the European Commission to YES Pharmaceutical Development Services GmbH, Germany, for infigratinib for the treatment of cholangiocarcinoma.

Key facts

Active substance
Infigratinib
Disease / condition
Treatment of cholangiocarcinoma
Date of first decision
21/08/2020
Outcome
Positive
EU designation number
EU/3/20/2329

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

YES Pharmaceutical Development Services GmbH
Bahnstrasse 42-46
61381 Friedrichsdorf
Germany
Tel: +49 6172 764 64 65
E-mail: laura.boteanu-jotzu@pharmalex.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating